Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) ELISA Kits

CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Zusätzlich bieten wir Ihnen CYP2C19 Antikörper (41) und CYP2C19 Proteine (3) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
CYP2C19 1557 P33261
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen

Top CYP2C19 ELISA Kits auf

Showing 3 out of 19 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Anbieter Lieferzeit Preis Details
Ratte 0.28 ng/mL 0.78-50 ng/mL 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
Human 0.264 ng/mL 0.62 ng/mL - 40 ng/mL 96 Tests Anmelden zum Anzeigen 13 bis 16 Tage
Human 0056 ng/mL 0.156 ng/mL - 10 ng/mL   96 Tests Anmelden zum Anzeigen 15 bis 17 Tage

Weitere ELISA Kits für CYP2C19 Interaktionspartner

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 19 (CYP2C19) Interaktionspartner

  1. study characterizes two new haplotypes in Scandinavian subjects, each containing two clinically important single nucleotide polymorphisms in CYP2C19 and CYP2C8, respectively

  2. In patients with high-risk TIA or minor ischemic stroke CYP2C19 loss of function SNP was associated with increased risk of adverse cerebrovascular outcomes in patients in the lowest quintile of estimated glomerular filtration rate.

  3. carriage of CYP2C19*2 polymorphism, in diabetes mellitus patients, might be a potential predictor of persisting clopidogrel platelet reactivity in these high-risk individuals

  4. We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment.

  5. The CYP2C19 polymorphism is associated with the frequency of major adverse cardiovascular events, but is not related to the incidence of bleeding after percutaneous coronary intervention in Japanese patients receiving clopidogrel.

  6. CYP2C19 genotype-based dosing combined with therapeutic drug monitoring will support individualization of Voriconazole dosing, and potentially will minimize toxicity and maximize therapeutic efficacy

  7. The combined genotype of CYP3A5*1/*3 and CYP2C19*1/*1 was associated with a low level of VASP phosphorylation, while either genotype was not. A multivariate analysis showed that high residual platelet reactivity during the cilostazol treatment, which was defined by a low response of platelet VASP phosphorylation to cilostazol, was an independent risk factor for the recurrence of thrombotic events.

  8. Minor allele frequencies (MAF) in a Puerto Rican population were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in HardyWeinberg equilibrium (HWE).

  9. The frequency distribution of alleles CYP2C19 in Yakuts is between that in the representatives of Mongoloid and Caucasian races, which can be explained by the history of forming the population of this particular region.

  10. The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes.

  11. CYP2C19*2 genotype-guided antiplatelet treatment remained a cost-effective strategy.

  12. CYP2C19 SNP was significantly associated with high on-treatment platelet reactivity and clinical outcomes after percutaneous coronary intervention.

  13. Polymorphisms of the CYP2C19 is associated with Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-Hematopoietic Stem Cell Transplantation.

  14. In a subject with predicted CYP2C19 PM phenotype, the PK of BMS-823778 was affected significantly by UGT1A4 polymorphism.

  15. Wild-type CYP2C19*1B and 30 isoforms were highly expressed in insect cells, and the enzymatic activities of CYP2C19 variants towards nebivolol hydroxylation were characterized. Three variants, CYP2C19*29 (K28I), L16F, and CYP2C19*23 (G91R), showed increased intrinsic clearance of >140% CYP2C19*1B.

  16. Carriage of a combination of mutant alleles in multiple genes including ITGB3+CYP2C19*2 or CYP2C19*2 + ITGA2 or CYP2C19*2 are possible predictors of CVE in patients after CABG

  17. Gene polymorphism testing results indicated that patients with CYP2C19*3 had a significantly higher incidence of high on-treatment platelet reactivity.

  18. CYP2C19 genotype only partially determines the CYP2C19 phenotypic appearance.

  19. appears that 5azaDC treatment affects an unidentified upstream regulator of both CYP2C19 and/or NR1I3. This is supported by the fact that the relationships between TF for CYP2C19 and the expression of this target gene in human liver samples only accounted for approximately 70% of the variability of CYP2C19 mRNA levels.

  20. For percutaneous coronary intervention in postoperative patients, research data is still lacking regarding clopidogrel dosage on the basis of different CYP2C19 genotypes.

CYP2C19 Antigen-Profil

Beschreibung des Gens

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Genbezeichner und Symbole assoziert mit CYP2C19

  • cytochrome P450 family 2 subfamily C member 19 (CYP2C19) Antikörper
  • cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) Antikörper
  • cytochrome P450 2C19 (CYP2C19) Antikörper
  • CPCJ Antikörper
  • CYP2C Antikörper
  • P450C2C Antikörper
  • P450IIC19 Antikörper

Bezeichner auf Proteinebene für CYP2C19

(R)-limonene 6-monooxygenase , (S)-limonene 6-monooxygenase , (S)-limonene 7-monooxygenase , CYPIIC17 , CYPIIC19 , S-mephenytoin 4-hydroxylase , cytochrome P-450 II C , cytochrome P450 2C19 , cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19 , cytochrome P450-11A , cytochrome P450-254C , flavoprotein-linked monooxygenase , mephenytoin 4'-hydroxylase , mephenytoin 4-hydroxylase , microsomal monooxygenase , xenobiotic monooxygenase , cytochrome P450 2C

1557 Homo sapiens
510380 Bos taurus
100534653 Ovis aries
Ausgewählte Anbieter für CYP2C19 (CYP2C19) ELISA Kits
Haben Sie etwas anderes gesucht?